Literature DB >> 22733221

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Jennifer A Schlichting1, Amr S Soliman, Catherine Schairer, David Schottenfeld, Sofia D Merajver.   

Abstract

Although it has been previously reported that patients with inflammatory breast cancer (IBC) experience worse survival than patients with other breast cancer (BC) types, the socioeconomic and ethnic factors leading to this survival difference are not fully understood. The association between county-level percent of persons below the poverty level and BC-specific (BCS) survival for cases diagnosed from 1990 to 2008 in the Surveillance, Epidemiology, and End Results (SEER) database linked to census derived county attributes was examined. A sub-analysis of cases from 2000 to 2008 also examined BCS survival by an index combining percent below poverty and less than high school graduates as well as metropolitan versus non-metropolitan county of residence. The Kaplan-Meier estimator was used to construct survival curves by stage, inflammatory status, and county-level socioeconomic position (SEP). Stage and inflammatory status stratified proportional hazards models, adjusted for age, race/ethnicity, tumor and treatment characteristics were used to determine the hazard of BCS death by county-level SEP. Kaplan-Meier survival curves indicated IBC has worse survival than stage matched non-IBC, (stage III IBC median survival = 4.75 years vs. non-IBC = 13.4 years, p < 0.0001). Residing in a lower SEP, non-metro county significantly worsens BCS survival for non-IBC in multivariate proportional hazards models. African American cases appear to have worse survival than non-Hispanic Whites regardless of inflammatory status, stage, county-level SEP, tumor, or treatment characteristics. This is the first study to examine IBC survival by SEP in a nation-wide population-based tumor registry. As this analysis found generally poorer survival for IBC, regardless of SEP or race/ethnicity, it is important that interventions that help educate women on IBC symptoms target women in various SEP and race/ethnicity groups.

Entities:  

Mesh:

Year:  2012        PMID: 22733221      PMCID: PMC4291081          DOI: 10.1007/s10549-012-2133-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  57 in total

1.  Reporting recommendations for tumor marker prognostic studies.

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

2.  Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.

Authors:  William F Anderson; Bingshu E Chen; Ismail Jatoi; Philip S Rosenberg
Journal:  Breast Cancer Res Treat       Date:  2006-05-10       Impact factor: 4.872

3.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

4.  Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?

Authors:  Monique G Lê; Rodrigo Arriagada; Jacqueline Bahi; Frédérique Pfeiffer; Mohamed Cammoun; Françoise Tabbane; Carole Rubino
Journal:  Breast       Date:  2005-09-29       Impact factor: 4.380

5.  Effects of health insurance and race on breast carcinoma treatments and outcomes.

Authors:  R G Roetzheim; E C Gonzalez; J M Ferrante; N Pal; D J Van Durme; J P Krischer
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

Review 6.  Breast cancer in African-American women.

Authors:  Lisa A Newman
Journal:  Oncologist       Date:  2005-01

7.  Inflammatory breast cancer and body mass index.

Authors:  S Chang; A U Buzdar; S D Hursting
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  Low rate of breast conservation surgery in large urban hospital serving the medically indigent.

Authors:  J T Dolan; T S Granchi
Journal:  Am J Surg       Date:  1998-12       Impact factor: 2.565

9.  Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.

Authors:  S Chang; S L Parker; T Pham; A U Buzdar; S D Hursting
Journal:  Cancer       Date:  1998-06-15       Impact factor: 6.860

View more
  21 in total

1.  The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.

Authors:  H Arias-Pulido; A Cimino-Mathews; N Chaher; C Qualls; N Joste; C Colpaert; J D Marotti; M Foisey; E R Prossnitz; L A Emens; S Fiering
Journal:  Breast Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.872

2.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

3.  Factors associated with neurodevelopment for children with single ventricle lesions.

Authors:  Caren S Goldberg; Minmin Lu; Lynn A Sleeper; William T Mahle; J William Gaynor; Ismee A Williams; Kathleen A Mussatto; Richard G Ohye; Eric M Graham; Deborah U Frank; Jeffrey P Jacobs; Catherine Krawczeski; Linda Lambert; Alan Lewis; Victoria L Pemberton; Renee Sananes; Erica Sood; Stephanie B Wechsler; David C Bellinger; Jane W Newburger
Journal:  J Pediatr       Date:  2014-06-19       Impact factor: 4.406

4.  Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Authors:  H Masuda; T M Brewer; D D Liu; T Iwamoto; Y Shen; L Hsu; J S Willey; A M Gonzalez-Angulo; M Chavez-MacGregor; T M Fouad; W A Woodward; J M Reuben; V Valero; R H Alvarez; G N Hortobagyi; N T Ueno
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

5.  Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.

Authors:  Jieqiong Liu; Kai Chen; Wen Jiang; Kai Mao; Shunrong Li; Min Ji Kim; Qiang Liu; Lisa K Jacobs
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-04       Impact factor: 4.553

Review 6.  Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Authors:  Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

7.  BRCA mutations in women with inflammatory breast cancer.

Authors:  Angelica M Gutierrez Barrera; Tamer M Fouad; Juhee Song; Rachel Webster; Nisreen Elsayegh; Anita L Wood; Atakan Demir; Jennifer K Litton; Naoto T Ueno; Banu K Arun
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

8.  Baby Boomers and Birth Certificates: Early-Life Socioeconomic Status and Cancer Risk in Adulthood.

Authors:  Antoinette M Stroup; Kimberly A Herget; Heidi A Hanson; Diana Lane Reed; Jared T Butler; Kevin A Henry; C Janna Harrell; Carol Sweeney; Ken R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-21       Impact factor: 4.254

Review 9.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

10.  Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.

Authors:  Jill K Schinkel; Shelia Hoar Zahm; Ismail Jatoi; Katherine A McGlynn; Christopher Gallagher; Catherine Schairer; Craig D Shriver; Kangmin Zhu
Journal:  Cancer Causes Control       Date:  2014-05-17       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.